x

Coronavirus

FDA OKs Third Antibody Drug for COVID-19 Cases

WASHINGTON — U.S. health officials have granted emergency authorization to a third antibody drug to help reduce hospitalizations and deaths due to COVID-19.

The FDA said Wednesday it authorized the drug from GlaxoSmithKline and Vir Biotechnology for people with mild-to-moderate cases of COVID-19 who face extra risks of severe illness, including seniors and those with underlying health problems.

There has been low demand for two similar drugs already available, due mainly to the logistical hurdles of delivering them and confusion about their availability. U.S. health officials have been trying to raise awareness of the treatments, connecting people who test positive for COVID-19 with information about nearby providers.

The drugs are delivered as a one-time intravenous infusion at a hospital or clinic and should be given within 10 days of the start of symptoms.

RELATED

ATHENS – While the New Democracy government is easing health restrictions for rabid anti-vaxxers, those fully vaccinated against COVID-19 may need a fourth shot in the autumn.

Top Stories

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

General News

PHILADELPHIA – The Federation of Hellenic Societies of Philadelphia and Greater Delaware Valley announced that the Evzones, the Presidential Guard of Greece will be participating in the Philadelphia Greek Independence Day Parade on March 20.

Video

Mitsotakis Addresses Boston College Graduation Ceremony

BOSTON - Greek Prime Minister Kyriakos Mitsotakis spoke at the 146th graduation ceremony of Boston College, held on Monday.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.